A Phase 1, Open-label, Randomized, Single-dose, Three-treatment, Three-way Crossover Pharmacokinetic Study to Evaluate the Relative Bioavailability of Etrumadenant (AB928) Tablet and Capsule Formulations and Food Effect on the Pharmacokinetics of the Tablet Formulation in Healthy Adult Participants
Latest Information Update: 02 Sep 2022
At a glance
- Drugs Etrumadenant (Primary) ; Etrumadenant (Primary)
- Indications Bladder cancer; Breast cancer; Colorectal cancer; Endometrial cancer; Gastrointestinal cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer
- Focus Pharmacokinetics
- Sponsors Arcus Biosciences
- 01 Apr 2022 Status changed from recruiting to completed.
- 16 Mar 2022 New trial record